UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

Form 6-K

 

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934

 

For the month of April, 2024.

 

Commission File Number: 000-51848

 

Avricore Health Inc.

 

(Exact name of registrant as specified in its charter)

 

1120-789 West Pender St, Vancouver, BC, V6C 1H2

 

(Address of principal executive office)

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): NO

 

Note: Regulation S-T Rule 101(b)(1) only permits the submission in paper of a Form 6-K if submitted solely to provide an attached annual report to security holders.

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): NO

 

Note: Regulation S-T Rule 101(b)(7) only permits the submission in paper of a Form 6-K if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled or legally organized (the registrant’s “home country”), or under the rules of the home country exchange on which the registrant’s securities are traded, as long as the report or other document is not a press release, is not required to be and has not been distributed to the registrant’s security holders, and, if discussing a material event, has already been the subject of a Form 6-K submission or other Commission filing on EDGAR.

 

 

 

 
 

 

Exhibits

 

The following exhibits are included in this form 6-K:

 

Exhibit No.   Description   Date Released
1   News Release-HEALTHTAB™ SIGNS AGREEMENT FOR MORE REXALL® PHARMACY LOCATIONS   2024-04-04
2   Notice Of Meeting   2024-04-15
3   Notice Of Meeting Amended   2024-04-16
4   Audited Annual Financial Statements   2024-04-29
5   Annual MD&A   2024-04-29
7   52-109FV1-Certification Of Annual Filings-CEO   2024-04-29
8   52-109FV1-Certification Of Annual Filings-CFO   2024-04-29
9   AB Form 13-501F1 (Class1 and 3B reporting issuers-participation fee)   2024-04-29
10  

News Release-AVRICORE HEALTH CORPORATE UPDATE AND AUDITED RESULTS FOR 2023

  2024-04-30

 

 
 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

  AVRICORE HEALTH INC.
     
Date: May 08, 2024 By “Kiki Smith”
    Kiki Smith
    Chief Financial Officer

 

SEC1815(04-09) Persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number

 

 

 


ATTACHMENTS / EXHIBITS

ATTACHMENTS / EXHIBITS

ex1.htm

ex2.htm

ex3.htm

ex4.htm

ex5.htm

ex7.htm

ex8.htm

ex9.htm

ex10.htm